 |
Rapamycin (mTOR) inhibitor |
|---|---|
| Trade Name | |
| Orphan Indication | Bone sarcoma |
| USA Market Approval | USA |
| USA Designation Date | 2005-08-09 00:00:00 |
| Sponsor | Merck Sharp & Dohme Corp.;S Merck & Co., Inc. Subsidiary, P. O. Box 1000, UG-2C50;North Wales, Pennsylvania, 19454 |
